IOVA Iovance Biotherapeutics Inc.

16.2
+0.59  (+4%)
Previous Close 15.61
Open 15.72
Price To Book 4.6
Market Cap 2000930542
Shares 123,514,231
Volume 2,062,113
Short Ratio
Av. Daily Volume 1,521,636

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 initiated March 2017. Poster session at SITC November 10, 2017. Data released January 24, 2018 showed 3/8 PRs.
LN-145
Head and neck cancer
Phase 2 completion of enrolment of final cohort due 2020. Updated Cohort 2 data due at ASCO June, 1, 2019. 8am.
LN-144 - lifileucel
Refractory metastatic melanoma
Phase 2 poster at ASCO June 1, 2019, 8am. Abstract released May 15, 2019 noted 44% ORR.
LN-145
Cervical cancer

Latest News

  1. 3 Biotech Stocks That Soared Last Week: Are They Buys?
  2. Why Snap, Kemet, and Iovance Biotherapeutics Jumped Today
  3. Here Are The Biotech Winners Ahead Of 2019's Biggest Cancer Meeting
  4. Here's Why Iovance Biotherapeutics Soared Today
  5. Iovance Issues Cancer Trial Updates Ahead Of ASCO Meeting, Sending Stock Skyward
  6. The Daily Biotech Pulse: FDA Nod For Roche, Trial Results For Agios, Iovance And MacroGenics
  7. Iovance Biotherapeutics Announces Updates to Tumor Infiltrating Lymphocyte (TIL) Therapy Clinical Programs
  8. Iovance Biotherapeutics, Inc. (IOVA) Q1 2019 Earnings Call Transcript
  9. Iovance Biotherapeutics: 1Q Earnings Snapshot
  10. Iovance Biotherapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update
  11. Here’s What Hedge Funds Think About Iovance Biotherapeutics, Inc. (IOVA)
  12. Iovance Biotherapeutics to Participate in Upcoming Conferences in May
  13. Iovance Biotherapeutics to Host First Quarter 2019 Financial Results Conference Call and Webcast on Tuesday, May 7, 2019
  14. PHIO: Activation in the Tumor Microenvironment
  15. Here's Why Iovance Biotherapeutics Soared on Wednesday
  16. Iovance Biotherapeutics to Present New Data from Ongoing Studies of Tumor-Infiltrating Lymphocyte (TIL) Therapy at 2019 American Society of Clinical Oncology (ASCO) Meeting
  17. Iovance Biotherapeutics Announces Clinical Programs Update
  18. Iovance Biotherapeutics Announces First Patient Dosed in Cohort 4 of Pivotal InnovaTIL-01 Study of Lifileucel in Metastatic Melanoma
  19. Iovance Biotherapeutics Presents Data at AACR Annual Meeting on T-Cell Diversity and Persistence in Patients Receiving Tumor Infiltrating Lymphocyte (TIL) Therapy Lifileucel
  20. Iovance Biotherapeutics Announces April Scientific and Investor Presentations